We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03525808
Recruitment Status : Completed
First Posted : May 16, 2018
Results First Posted : December 20, 2021
Last Update Posted : December 20, 2021
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To demonstrate safety and effectiveness of lumen-apposing metal stents for resolution of walled off pancreatic necrosis (WONs) in patients with WONs with solid component >30%.

Condition or disease Intervention/treatment Phase
Walled Off Pancreatic Necrosis Device: AXIOS Not Applicable

Detailed Description:
This study is a prospective, single arm, multi-center trial. Treatment of up to 40 patients will take place at up to 6 clinical centers. Patients who meet all eligibility criteria will receive the AXIOS stent for up to 60 days stent indwell and 6 months follow-up after stent removal.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Single-arm Study of Endoscopic Ultrasound-Guided Drainage of Walled-off Pancreatic Necrosis With Lumen-Apposing Metal Stents
Actual Study Start Date : September 5, 2018
Actual Primary Completion Date : March 31, 2020
Actual Study Completion Date : October 2, 2020

Arm Intervention/treatment
Experimental: AXIOS
Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
Device: AXIOS
Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.

Primary Outcome Measures :
  1. Number of Participants With Resolution of WON With Endoscopic Drainage [ Time Frame: Up to 60 Days ]
    Resolution of WON with endoscopic drainage defined as radiographic decrease of WON size to ≤ 3cm evaluated by CT scan or MRI

  2. AXIOS Stent Related or WON Drainage Procedure Related Serious Adverse Events [ Time Frame: Through study completion, average of 8 months ]
    AXIOS stent related or WON drainage procedure related serious adverse events

Secondary Outcome Measures :
  1. Symptom Reduction [ Time Frame: Through study completion, average of 8 months ]
    Reduction of WON-related clinical symptoms. Note: WON-related symptoms as defined in Inclusion Criteria #4

  2. Technical Success [ Time Frame: Intraoperative (Stent placement) ]

    Technical AXIOS stent placement success, defined as placement in desired location using endoscopic/EUS techniques per standard of practice.

    Technical AXIOS stent removal success, defined as ability to remove the AXIOS stent using an endoscopic snare or forceps or graspers without AXIOS stent removal related serious adverse events.

  3. Drainage Procedural Time [ Time Frame: Intraoperative (Stent placement) ]
    Time elapsed between initial puncture of the WON with electrocautery to endoscope retrieval.

  4. Resolution of WON: Radiographic Resolution Evaluated by MRI or CT [ Time Frame: Through study completion, average of 8 months ]
    Resolution of WON with or without necrosectomy by 6 months post AXIOS stent removal.

  5. Time to WON Resolution [ Time Frame: Up to 60 Days ]

    Time to WON resolution using same definition as for primary endpoint, namely:

    • Resolution of WON with endoscopic drainage defined as radiographic decrease of WON size to ≤ 3cm evaluated by CT scan or MRI.

  6. WON Recurrence [ Time Frame: Through study completion, average of 8 months ]
    Recurrence of WON after initial resolution and up to 6 months post AXIOS stent removal.

  7. Stent Lumen Patency [ Time Frame: Intraoperative (Stent placement through stent removal) ]

    Stent lumen patency, evaluated via imaging or direct visual inspection with endoscope, and defined as one or both of the following:

    • Drainage through AXIOS stent visualized from the stomach or bowel, and/or
    • Visual confirmation of AXIOS stent lumen patency

  8. Fluoroscopy [ Time Frame: Intraoperative (Stent placement through stent removal) ]
    Fluoroscopy (time) per endoscopic procedure.

  9. Incidence of New Organ Failure [ Time Frame: Up to 60 days ]
    Number of participants with new organ failure from drainage procedure to WON resolution.

  10. Change in SF-12 Score [ Time Frame: Difference from baseline to stent removal (up to 60 days) visit ]
    *Change* in Quality of Life score (SF-12 questionnaire) from *baseline to stent removal*. The SF-12 is a health-related quality-of-life questionnaire consisting of twelve questions that measure eight health domains to assess physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 22 and 75 years old
  • Severe or moderately severe acute necrotizing pancreatitis, defined per the 2012 Revised Atlanta Classification.
  • WON resulting from necrotizing pancreatitis per contrast-enhanced CT with the following characteristics, per the 2012 Revised Atlanta Classification:

    • Heterogeneous with liquid and non-liquid density with varying degrees of loculations (some may appear homogeneous)
    • Well defined wall
    • Location-intrapancreatic and/or extrapancreatic
  • Infected WON or symptomatic sterile WON Note: WON-related symptoms may include: pain, fever, leukocytosis, failure to thrive or deterioration of overall heath score, gastric outlet obstruction (GOO), weight loss, biliary obstructive symptoms, systemic inflammatory response syndrome (SIRS), deteriorating organ function, chronic nausea, lethargy, and inability to eat or gain weight
  • Imaging suggestive of greater than 30% necrotic material
  • WON ≥ 6cm in size
  • Eligible for endoscopic intervention
  • Acceptable candidate for endoscopic transluminal drainage
  • Patient understands the study requirements and the treatment procedures and provides written Informed Consent
  • Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post imaging study

Exclusion Criteria:

  • Pseudocyst
  • Cystic neoplasm
  • Untreated Pseudoaneurysm > 1cm within the WON
  • More than one WON clearly separated and requiring drainage
  • WONs that require dual modality interventions (endoscopic and percutaneous) from the beginning (i.e. deep paracolic space involvement that is inaccessible through the central drainage access)
  • Prior surgical, interventional radiology or endoscopic procedures for the treatment of the WON
  • Abnormal coagulation:

    • INR > 1.5 and not correctable
    • presence of a bleeding disorder
    • platelets < 50,000/mm3
  • Intervening gastric varices or unavoidable blood vessels within the access tract (visible using endoscopy or endoscopic ultrasound)
  • WON that poorly approximates the GI lumen (≥1cm away)
  • Pericolic gutter necrosis
  • Pelvic necrosis
  • Prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient
  • Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study
  • Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03525808

Layout table for location information
United States, Colorado
University of Colorado, Denver
Aurora, Colorado, United States, 80045
United States, Georgia
Emory University Healthcare
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana University Health
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: Barham K Abu Dayyeh, MD Mayo Clinic
  Study Documents (Full-Text)

Documents provided by Boston Scientific Corporation:
Study Protocol  [PDF] August 16, 2018
Statistical Analysis Plan  [PDF] May 18, 2018

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT03525808    
Other Study ID Numbers: E7116
First Posted: May 16, 2018    Key Record Dates
Results First Posted: December 20, 2021
Last Update Posted: December 20, 2021
Last Verified: December 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Boston Scientific Corporation:
Pancreatic necrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis, Acute Necrotizing
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases